Tixagevimab/cilgavimab or placebo for COVID-19 in ACTIV-2: Safety, pharmacokinetics and neutralizing and anti-drug antibodies

Tixagevimab/cilgavimab or placebo for COVID-19 in ACTIV-2: Safety, pharmacokinetics and neutralizing and anti-drug antibodies

Summary: Monoclonal antibodies have potential as rapidly developable agents for treatment and prevention of emerging viruses. The ACTIV-2 trial randomized persons with mild-moderate COVID-19 to the monoclonal antibody combination tixagevimab/cilgavimab via intramuscular injection (600 mg IM) or infu...

ver descrição completa

Detalhes bibliográficos
Main Authors: Rachel A. Bender Ignacio, Kara W. Chew, Carlee Moser, Judith S. Currier, Joseph J. Eron, Arzhang Cyrus Javan, Mark J. Giganti, Justin Ritz, Michael Gibbs, Hervé Tchouakam Kouekam, Mark T. Esser, Eric S. Daar, Manish Choudhary, Rinki Deo, Courtney V. Fletcher, Jonathan Z. Li, Michael D. Hughes, Davey Smith, David Alain Wohl
Formato: Artigo
Idioma:English
Publicado em: Elsevier 2025-03-01
Colecção:iScience
Assuntos:
Health sciences
Medicine
Medical specialty
Immunology
Acesso em linha:http://www.sciencedirect.com/science/article/pii/S2589004225001981

Internet

http://www.sciencedirect.com/science/article/pii/S2589004225001981

Registos relacionados